Bevacizumab doesn't prolong survival in stage II-III colon CA

December 12, 2012
Bevacizumab doesn't prolong survival in stage II-III colon CA
For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin does not prolong disease-free or overall survival, according to a study published online Dec. 10 in the Journal of Clinical Oncology.

(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study published online Dec. 10 in the Journal of Clinical Oncology.

Carmen J. Allegra, M.D., from the University of Florida in Gainesville, and colleagues examined the disease-free and overall survival at a median of five years of follow-up in a trial designed to assess the safety and efficacy of adding to FOLFOX6. A cohort of 2,673 patients with stage 2 to 3 were randomly assigned to receive either modified FOLFOX6 once every two weeks for six months, or modified FOLFOX6 once every two weeks for six months plus bevacizumab for 12 months beginning concurrently with chemotherapy.

The researchers found that the addition of bevacizumab was not associated with increased disease-free survival (hazard ratio [HR], 0.93; P = 0.35). Bevacizumab had a different effect on disease-free survival before and after 1.25 years. There was no difference in overall survival for the two treatment groups (HR, 0.95; P = 0.56) or for those with stage 3 disease (HR, 1.0; P = 0.99).

"On the basis of our results, which showed a lack of benefit associated with the use of bevacizumab for one year along with six months of FOLFOX chemotherapy, bevacizumab should not be used for the management of patients with stage 2 or 3 colon cancer in the adjuvant setting," the authors write.

Several authors disclosed financial ties to Genentech, which manufactures bevacizumab.

Explore further: Bevacizumab active in HIV-linked Kaposi's sarcoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012

(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Nonoperative approach feasible in advanced colon cancer

August 9, 2012

(HealthDay) -- Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy ...

Recommended for you

New role for an old protein: Cancer causer

September 3, 2015

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.